Vulvodynia Clinical Trial: The First Drug Being Developed Specifically for This Condition

There is no medication approved specifically for vulvodynia. Not a single one. John Connell and his team are trying to change that. In this episode, I sit down with John Connell, Chief Scientific Officer at MAC Clinical Research — one of the UK's longest-established contract research organisations. John has spent over 35 years in clinical research, and has been working with Danish biotech Initiator Pharma for the past six or seven years to develop pudafensine: a first-of-its-kind drug being investigated specifically for vulvodynia. Pudafensine works by increasing dopamine levels in the brain — a chemical messenger most people associate with pleasure and reward, but one that also plays a crucial role in pain modulation. Unlike the treatments many of us are already on (think amitriptyline or SNRIs), pudafensine is not repurposed from another condition. It is being specifically developed with this type of pain in mind. Preclinical studies showed early promise, and in a subsequent study on healthy volunteers using a capsaicin pain model, a single dose reduced allodynia more effectively than pregabalin — and with fewer side effects. We get into the science of how the drug works, what the preclinical and early human data is showing, and what it actually looks like to take part in the trial. John also speaks to the bigger picture: why vulvodynia has been so chronically under-researched, why this study is pivotal for the future of drug development in this space, and what it would mean for the field if a positive signal is found. If you're in the UK, aged 18–65, and have experienced vulvar pain for 12 months or more (with or without a formal diagnosis), you may be eligible to take part. Participants can receive up to £1,730 plus reasonable travel expenses. Clinics are in Manchester and Blackpool. Find out more and sign up here: https://researchforyou.co.uk/vulvodyn... In paid partnership with @mac_clinicalresearch In this episode: • Why there is still no approved drug for vulvodynia — and why diagnosis can take years • What pudafensine is and how it targets the dopamine system to interrupt pain signalling • How it differs from amitriptyline, SNRIs, and other treatments many listeners are already on • The capsaicin pain model study: what it showed, and why the results were so significant • What the current clinical trial actually involves, from first contact to final visit • Who is eligible to take part and what would exclude someone • Why this particular study is a pivotal moment for vulvodynia drug development • What it would mean — for patients, for the industry — if this works